FDA PET guidance vacated by Federal appeals court; policy required formal rulemaking.
This article was originally published in The Gray Sheet
Executive SummaryFDA's PET GUIDANCE NEEDED PUBLIC NOTICE; AGENCY VIOLATED FEDERAL LAW, Washington, D.C. appeals court determines Oct. 28, reversing a district court summary judgment in Syncor International Corp., et al. v. Donna E. Shalala, et al. The lower court had found that although FDA's February 1995 guidance on positron emission tomography radiopharmaceuticals was not a guidance but an interpretive rule, it was not required to give notice of proposed rulemaking to the public ("The Gray Sheet" March 17, p. 9).
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.